About drug makers', um, reputation
The biotech industry has found itself smack in the middle of a florid debate on drug pricing policy — and one trade association’s leaders aren’t happy with their reputation.
“We’re the worst perceived entity [in America], and that’s ridiculous,” said Jeremy Levin, who recently began his term as chair of the Biotechnology Innovation Organization’s board.
Levin, a social liberal but fiscal conservative, has previously suggested that federal legislation targeting out-of-pocket costs might be one way to fix the drug pricing problem. But during a Monday meeting, the industry group’s leaders made it clear they hadn’t seen many proposals they liked.
STAT’s Nicholas Florko listened to what BIO had to say.
Levin, a social liberal but fiscal conservative, has previously suggested that federal legislation targeting out-of-pocket costs might be one way to fix the drug pricing problem. But during a Monday meeting, the industry group’s leaders made it clear they hadn’t seen many proposals they liked.
STAT’s Nicholas Florko listened to what BIO had to say.
.png)
No hay comentarios:
Publicar un comentario